Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense® E3 Sensor and adhesive patches contain silicone. If you have any concerns about allergic reaction to silicones, contact your health care professional prior to use.
The proximity of the Eversense® E3 Sensor with medicated patches has not been studied. Please contact your health care professional for advisement.
Tell your health care professional if you have any skin conditions. The Eversense® adhesive patch should only be applied to intact, healthy skin.
The Eversense® E3 Sensor is a miniaturized fluorometer that uses fluorescent intensity to measure glucose in interstitial fluid. The sensor is implanted subcutaneously (under the skin) on the upper arm, leaving no part of the sensor protruding from the skin. The sensor remains in place and provides
CGM measurements for the operating life of the sensor for up to 180 days.
The sensor is encased in a biocompatible material and utilizes a unique fluorescent, glucose indicating polymer. A light emitting diode embedded in the sensor excites the polymer, and the polymer then rapidly signals changes in glucose concentration via a change in light output. The measurement is then relayed to the smart transmitter. Measurements are completed automatically and require no action by the user.
The sensor is approximately 3.5 mm x 18.3 mm and has a silicone ring that contains a small amount of dexamethasone acetate, an anti-inflammatory steroid drug. The dexamethasone acetate minimizes inflammatory responses, very similar to common medical devices, such as pacemakers.
The Eversense E3 Sensor includes the sacrificial boronic acid (SBA) design modification.
Your Eversense Inserter will explain and perform the simple and quick steps to remove the sensor. You will be fully awake during the approximately 5-minute removal procedure.
Step 1: Site preparation – the sensor site will be cleaned, disinfected, then anesthetized using lidocaine.
Step 2: Incision – a small (~ 5-6mm) incision will be made at the sensor site.
Step 3: Sensor removal – the sensor will be removed and discarded.
Step 4: Site closure – once removed, the incision will be closed with Steri-Strips™ (sutures may be used depending on provider’s preference).
The Eversense® E3 CGM System has not been tested using insertion sites other than the upper arm.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060